Protai ⚠ Under review

Under review — some data on this profile may be inaccurate and is being re-verified.

AI-powered drug discovery platform that deeply maps disease at the protein level.

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2021
Last updated 2026-07-26
Total raised
$20.0M
Last: Undisclosed Round 2023-03
Stage
Seed
Founded
2021
Headcount
28
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Protai is an AI-powered drug discovery startup that combines deep proteomics research with machine learning to combat complex diseases. The company has developed an end-to-end AI-based platform that comprehensively maps the course of a disease at the protein level, enhancing the ability to observe cellular function and improve drug discovery. Protai's technology analyzes proteins, their activity, and interactions to predict changes that will lead to effective disease cures and drug development. They aim to improve patient response prediction to drugs and discover novel drug targets that genomic approaches may have overlooked.

Funding history · 2 rounds · $20.0M total

2023-02
Seed Extension $12.0M
★ Grove Ventures★ Pitango HealthTech
2021-12
Seed $8.0M
★ Grove VenturesPitango HealthTech

Headcount over time

From 10 (2021-12) to 28 (2026-03) · +18 (+180%) · 29 points · source: Finder history + radar grounding
290 2021-12 2026-03

Q&A

What is Protai's primary focus in drug discovery?
Protai focuses on AI-powered drug discovery, utilizing deep proteomics research and machine learning to map diseases at the protein level and improve drug development.
How much funding has Protai raised in total?
Protai has raised a total of $20,000,000.
When did Protai complete its most recent funding round and for what amount?
Protai completed a Seed funding round in March 2023, raising $12,000,000.
Which investors participated in Protai's Seed round in January 2022?
Protai's Seed round in January 2022 included investments from Grove Ventures.
What is the current employee count for Protai?
Protai has 28 employees, falling within the 11-50 employee bucket.
What recognition did Protai receive in May 2026?
In May 2026, Protai was awarded as one of the Most Innovative Life Science Startups at Biomed Israel 2026.
What is Protai's primary sector classification?
Protai's primary sector classification is Health Tech & Life Sciences.

Team · 2

Eran Seger
Founder · CEO & Co-Founder
Kirill Pevzner
Founder · CTO & Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceMachine LearningPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

data-analyticsbiotechnologydecision-supportdisease-managementproteinsdigital-healthcareartificial-intelligencedrug-discoverypersonalizationsoftware-platformpharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteprotai.bio
LinkedInlinkedin.com/company/74514047

Identifiers & details

Legal nameProtei Bio Ltd.
Founded2021
Employees (exact)28

Radar intelligence

Patents

EPO51

Publications (Crossref)

Works3

GitHub

Top reposco-folding-benchmark

Web history (Wayback)

Domainprotai.bio

Certificate / subdomain footprint

Subdomains4

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516427895
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2021-07-05
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events1 — charge (1)
Registered addressשוהם 5 רמת גן

Recent registry events

DateEvent
2025-11-06סילוק שעבוד